APLM Stock — Apollomics Inc. Class A Ordinary Shares

Apollomics Inc. Class A Ordinary Shares (APLM)

Updated October 16, 2026.

APLM is a Stock. Total return is -97.9% over the past 4.9 years, 175.7 points behind SPY at 77.8%.

Apollomics is a clinical-stage biopharmaceutical company developing oncology therapies focused on immunotherapy and targeted molecular pathways to treat cancer. The company's pipeline includes multiple product candidates in Phase 1 and Phase 2 trials, such as Vebreltinib for non-small cell lung cancer and various antibody-based immuno-oncology therapies. As an early-stage biotech company, it does not currently have approved products generating revenue and does not distribute dividends; it may appeal to investors seeking exposure to clinical-stage drug development with higher risk and growth potential rather than income generation.

APLM performance versus SPY

Price and return data through 2026-10-16.

Total return is -97.9% over the past 4.9 years, 175.7 points behind SPY at 77.8%. Over the past year its total return — price change plus distributions reinvested — is -34.0%. Its deepest 1-year drawdown was 68.3%.

APLM key facts

Asset type

Stock

Asset class

Equity

Inception date

11/26/2021

Distribution frequency

None

Last close

$21.10 (as of 2026-10-16)

Market cap

$61,505,762

Average volume

6231.0

Beta

1.537

Payout ratio

0.0%

EPS

$-7.57

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

APLM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 68.3%.

Who may consider APLM — and who may not

It is a weaker fit for investors who need monthly cash flow (APLM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on APLM

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions